Life Sciences BC News, August 15, 2024 | |
The Public Policy Forum (PPF) released a new report that underscores the urgent need for sweeping reforms to enhance Canada’s health security. As featured in the Globe & Mail, the report outlines how Canada is the only G7 country that doesn’t have a national health security and emergency coordination agency. The report is based on work done by PPF’s Life Sciences Forum, co-chaired by LSBC’s Wendy Hurlburt and Berkeley Vincent, President of J&J Innovative Medicine Canada. Read the full report here. | |
LSBC celebrates the induction of Dr. Allen Eaves and the late Dr. Connie Eaves into the BC Innovators Hall of Fame. Sadly, the honour will be bestowed posthumously for Connie, who passed on March 7 this year, at the age of 79. Read the article by Business in Vancouver here. | |
The Government of Canada announces details of the new Canadian Entrepreneurs’ Incentive. This incentive would reduce the inclusion rate to one-third on a lifetime maximum of $2 million in eligible capital gains. Other enhancements to the incentive were announced which include eliminating the founder requirement and reducing ownership requirements, among others. The government invites all interested Canadians to email their comments on these enhancements, which are detailed in draft legislation, to consultation-legislation@fin.gc.ca by September 11, 2024. | |
|
Take a sneak peek at our profile of Chinook Therapeutics, a Novartis Company, winner of the 2024 Life Sciences BC Deal of the Year Award. Chinook is making great strides in kidney disease with their pipeline of renal precision medicines. They were recently acquired by Novartis, a move that speaks to the global value of their work. Watch the clip here.
| |
Raise a toast to Chinook and other award winners at our upcoming 2024 LSBC Awards Gala presented by Farris on September 10! We're delighted to gather BC's life sciences community for a festive evening celebrating our sector and this year’s award winners. | |
|
Tickets are selling fast for this year's Awards Gala presented by Farris. It’s a great opportunity to meet and mingle with sector leaders, connect with the life sciences community, and learn about some of the trailblazers leading the charge.
Get your tickets to the LSBC Awards Gala today.
| |
|
Tell us about your lab space needs: LSBC pulse survey
LSBC will be undertaking a short pulse survey by phone this August to gather important aggregate information on our sector’s lab space needs. Data will be anonymized and aggregated and available to the sector, including government, for planning purposes.
Help support this important data collection through participating in our very short phone survey if contacted. Or please reach out to us at Labspace@lifesciencesbc.ca
| |
|
Moderna and Coursera launch a free course on mRNA technology. mRNAs as Medicines, a three-module course designed by experts at Moderna offers a comprehensive understanding of mRNA medicines, how they work and their potential applications. It is available for free to Coursera learners. Read more.
Genome BC released its annual report highlighting how strategic partnerships are fueling the growth of BC’s thriving life sciences sector. Read more.
Stryker will acquire AI-assisted virtual care company Care.ai. Care.ai specializes in AI-assisted virtual care workflows, smart room technology and ambient intelligence solutions. Read more.
Filament Health announces major Intellectual Property expansion. Filament’s industry-leading global IP portfolio contains 46 allowed patents relating to the extraction, purification, standardization, and delivery of naturally derived psychedelic APIs. Read more.
| |
|
BIOTECanada announces 2025 pre-budget submission with recommendations for funding, investment capital, and a recurring allowance to support Canadian access to safe and cost-effective vaccines. Read more.
The Government of Canada is investing more than $43 million to support 14 new clinical trials focused on preparing Canada to respond to future health emergencies and advancing the country’s life sciences sector. Read more.
| |
Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Learn more. | |
|
Congratulations to Pfizer Canada, who was ranked as the most reputable Canadian pharmaceutical company by 100 Patient Advocacy Groups in the 2023 PatientView survey. This honour recognizes Pfizer Canada’s dedication to patient-centricity. Read more.
Bausch Health announced the winners of their 2024 Gastrointestinal Health Scholars Program. The program awards 10 students living with a GI disease with a scholarship to further their higher education. Read more.
| |
|
Dr. Matthew D. Ronsheim has joined Xenon as their new Chief Operating Officer. Dr. Ronsheim brings 25 years of experience in all stages of drug development, from discovery to commercial launch, to the role. He joins Xenon from Innoviva Specialty Therapeutics, where he served as President. Read more.
Frontage announced the promotion of Dr. Wentao Zhang to Chief Strategy Officer. Dr. Zhang will be responsible for overseeing Frontage’s comprehensive services in drug discovery, preclinical safety, and pharmaceutical development. Read more.
| |
|
The Trade Accelerator Program (TAP) is a 5-day program offering essential strategy, resources and mentorship, equipping small and medium-sized businesses to scale up, develop and activate an export plan. The Greater Vancouver Board of Trade is offering a full bursary to LSBC members - which covers the full program cost of $5,000. When applying online, companies can simply mention Life Sciences BC as their referral contact to receive the bursary. Learn more.
Ontario Bioscience Innovation Organization is accepting applications for the third cohort of their Health Science Technology Training, a 14+ week upskilling program for software and date professionals looking to transition to a career in health tech. Apply by August 25, 2024! Learn more.
Applications are open for the Fall 2024 cohorts of the adMare Academy BioInnovation Scientist Programs: Foundations and Industry Essentials. These two programs offer early-career scientists and post-secondary students a comprehensive look into therapeutics development and the biopharma industry. Apply by September 20, 2024, for Foundations and October 23, 2024 for Industry Essentials. Learn more.
The National Research Council of Canada is leading a delegation to South Korea for the Canadian circular battery technologies mission from January 13-17, 2025. Canadian businesses interested in exploring opportunities in the Indo-Pacific region are welcome to register by September 16, 2024. Learn more.
Calling all Canadian biotechnology companies! The Accelerating Clinical Trials Consortium is hosting its Third Annual Meeting on October 9-10, 2024, in Quebec City. Apply by August 16, 2024 for the opportunity to pitch your innovations to ACT Canada researchers. Learn more.
| See our expanded list of current life sciences opportunities on our website. | |
|
CereCura Nanotherapeutics is a preclinical neuroscience-focused biotechnology company developing lipid nanoparticle-RNA therapies for a wide range of brain disorders. CereCura’s disease-agnostic approach aims to overcome barriers to CNS therapeutics by harnessing the brain to produce its own medicine. Our mission is to pioneer a novel class of genetic drugs for untreated brain disorders. Learn more.
| |
|
Until next week!
LSBC Team
| |
|
September 10 - Join us on September 10, 2024, as we celebrate excellence in life sciences at the 26th Annual Life Sciences BC Awards, presented by Farris.
This distinguished occasion brings together British Columbia’s vibrant life sciences community to celebrate the outstanding achievements of our peers and recognize the tireless efforts of those who have devoted their careers to advancing health innovations.
| |
|
October 29 & 30 - Life Sciences BC is pleased to announce the 9th annual Invest in BC presented by Lumira Ventures conference.
This highly anticipated event serves as a premier gathering for healthcare innovators in British Columbia, connecting them with global investors. This year we’ve reimagined the conference, offering attendees a dynamic two-day program featuring 30+ company pitches from pre-seed to public.
| | |
|
|
Moderna and Coursera Launch Free Course on mRNA Technology
Moderna, Inc. and Coursera announced a partnership to launch mRNAs as Medicines, a three-module course designed by experts at Moderna that offers a comprehensive understanding of mRNA medicines, how they work and their potential applications...Read more.
| | |
|
|
BioTalent Canada Named 5-Star Diversity, Equity and Inclusion Employer by Canadian HR Reporter
BioTalent Canada has been named a 5-Star Diversity, Equity and Inclusion Employer for 2024 by Canadian HR Reporter. The award, now in its third year, recognizes companies whose diversity, equity and inclusion programs advance change in the workplace...Read more.
| | |
|
|
adMare BioInnovations Opens Applications for the Fall Cohorts of the BioInnovation Scientist Programs
adMare BioInnovations is delighted to open applications for the Fall 2024 cohorts of the adMare Academy BioInnovation Scientist Programs: Foundations and Industry Essentials...Read more.
| | |
|
|
Bausch Health Announces 2024 Gastrointestinal Health Scholars Program Winners
Bausch Health Companies and its gastroenterology business, Salix Pharmaceuticals, announced the recipients of its 2024 Salix Gastrointestinal Health Scholars Program. For the fifth year, Bausch Health is proud to award 10 deserving students living with a GI disease $10,000 each...Read more.
| | |
|
|
Filament Health Announces Major Intellectual Property Expansion
Filament Health, a clinical‐stage natural psychedelic drug development company, announced that it has expanded its intellectual property portfolio with the acceptance of twelve patents by IP Australia for processes relating to the development of botanical psychedelic drugs…Read more.
| | |
|
|
Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer
Xenon Pharmaceuticals, a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, announced the appointment of Matthew D. Ronsheim, Ph.D. as COO and a member of the Xenon senior executive team…Read more.
| | |
|
|
Pfizer Canada Ranked #1 by 100 Canadian Patient Advocacy Groups
Pfizer is proud to announce that it has been ranked as the most reputable pharmaceutical company in Canada by Patient Advocacy Groups in the 2023 PatientView survey...Read more.
| | |
|
|
Stryker to Acquire AI-assisted Virtual Care Company Care.ai
Stryker announced that it entered into a definitive agreement to acquire Care.ai. Care.ai specializes in AI-assisted virtual care workflows, smart room technology and ambient intelligence solutions...Read more.
| | |
|
|
PharmAla Comments on USFDA Decision Regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
PharmAla Biotech is disappointed in the decision made by the US FDA to request that Lykos Therapeutics complete a third confirmatory Phase 3 trial prior to allowing the approval of MDMA assisted therapy for the treatment of Post Traumatic Stress Disorder…Read more.
| | |
|
|
Frontage Announces the Promotion of Dr. Wentao Zhang as Chief Strategy Officer
Frontage Laboratories Inc. announced that Dr. Wentao Zhang has been promoted to Chief Strategy Officer and will continue to report to Dr. Abdul Mutlib, Chief Executive Officer…Read more.
| | |
|
|
Innovative Anti-Nausea Smartwatch EmeTerm® Smart Set to Launch on Indiegogo
EmeTerm® Smart uses patented hybrid technology to seamlessly integrate the functionality of a smartwatch with that of an anti-nausea wristband, ensuring a carefree and healthy life for all. EmeTerm® Smart is launching on Indiegogo as the world’s first anti-nausea smart watch…Read more.
| | |
|
|
Laboratory Assistant, Lab & Facilities
The Lab Operations Assistant will be responsible for a variety of tasks, including consumables inventory management, restocking lab supplies, shipping/receiving and maintaining equipment in good working order...Learn more
| | |
|
|
Senior Animal Care Technician (18 month contract)
The Sr. Animal Care Technician reports to the Director, In Vivo Resources and is responsible for the various technical procedures that support the scientific research conducted during the execution of in vivo studies...Learn more
| | |
|
|
Principal Scientist – Discovery Protein Sciences
The Therapeutic Discovery organization is seeking to fill a position at the Principal Scientist level in our Discovery Protein Sciences group in Vancouver, Canada. This position, which is laboratory-based, will support the design and generation of complex biological molecules...Learn more
| | |
|
|
Senior Associate, LNP Internal Manufacturing
As the Sr. Associate, Internal LNP Manufacturing, you will have a key role manufacturing, testing and shipping LNP drug products for multiple partner programs as part of this crucial department...Learn more
| | |
|
|
Senior Manager, CMC, Quality Control
The Senior Manager, CMC, Quality Control will work flexibly across several small molecule drug development programs with an emphasis on managing outsourced testing and stability program for the cGMP API and drug product manufacturing and testing campaigns...Learn more
| | |
|
|
Clinical Scientist 1 or 2
The Clinical Scientist 1 or 2 will be a member of a highly collaborative Clinical Development team, with involvement in a diverse range of activities. This position reports to the Vice President, Clinical Development...Learn more
| | |
|
|
Biomanufacturing Training
Brunel has a current opportunity for a Biomanufacturing Trainer on a permanent basis. The position will be based in Vancouver. For further information about this position please apply...Learn more
| | |
|
|
Research Technician 2, Resource Facility
Xenon is seeking a Research Technician 2, Resource Facility to join our animal care team. This position will provide husbandry and facility maintenance to support preclinical research in drug discovery...Learn more
| | |
|
Post a Job on the LSBC Website | |
LSBC Membership Discounts on Job Postings
As an LSBC member, your first five job postings EARN a free repost on BioTalent Canada's The Petri Dish. After your first five posts, you will also receive 25 per cent off all job postings on The Petri Dish. Want more info? Contact talent@lifesciencesbc.ca.
| |
|
Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking™ platform. By using AI, we can review and optimize drug candidates at a much greater pace than ever before.
The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners.
Further information may be found at www.rakovinatherapeutics.com. Learn more.
|
|
If you haven't already, sign-up for this and our weekly events newsletter | |
Follow LSBC on Social Media | | | | |
